Paper No. __ Filed: March 17, 2016

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

PAR PHARMACEUTICAL, INC., WOCKHARDT BIO AG, and AMNEAL PHARMACEUTICALS LLC, Petitioners,

v.

JAZZ PHARMACEUTICALS, INC., Patent Owner.

Case IPR2015-00554¹ Patent 7,668,730 B2

PETITIONERS PAR PHARMACEUTICAL, INC.'S
AND AMNEAL PHARMACEUTICALS LLC'S RESPONSE
TO PATENT OWNER'S NOTICE REGARDING NEW
ARGUMENTS AND EVIDENCE IN PETITIONERS' REPLY

Mail Stop "PATENT BOARD"

Patent Trial and Appeal Board U.S. Patent and Trademark Office P.O. Box 1450 Alexandria, VA 22313-1450

¹ Case IPR2015-01818 has been joined with this proceeding.



Petitioners' Response to Patent Owner's March 10, 2016 Notice

Pursuant to the Board's March 3, 2016 e-mail, Petitioners Par Pharmaceutical, Inc. and Amneal Pharmaceuticals LLC identify the following portions of Patent Owner's Response (Paper No. 39) to which the arguments and evidence that Patent Owner Jazz Pharmaceuticals, Inc. identified in its March 10, 2016 Notice (Paper No. 50) respond:

- 1. The arguments and evidence Jazz identified in Paragraph 1 of its Notice respond to the arguments in Patent Owner's Response starting on page 9, after subheading (c), through page 12, line 2; including Jazz's argument that: "the redactions in Ex. 1004 do not evidence public accessibility before the critical date" (page 10); and "Petitioners ignore that the Briefing Booklet is addressed to a limited Advisory Committee panel that was responsible for reviewing the Xyrem drug application for FDA approval." (page 11).
- 2. The arguments and evidence Jazz identified in Paragraph 2 of its notice respond to arguments in Patent Owner's response starting on page 11, line 1, through page 12, line 2; including Jazz's argument that: "Petitioners ignore that the Briefing Booklet is addressed to a limited Advisory Committee panel that was responsible for reviewing the Xyrem drug application for FDA approval." (page 11). Further, the evidence to which Jazz refers was provided with the Petition. *See* Paper No. 2.



Petitioners' Response to Patent Owner's March 10, 2016 Notice

3. The arguments and evidence Jazz identified in Paragraph 3 of its notice respond to arguments in Patent Owner's response starting on page 5, line 7 (under subheading (a)) through line 17; including Jazz's argument that: "[t]he dates on the documents do not establish public accessibility before the critical date" (page 5). Further, the evidence Jazz refers to was provided with the Petition. *See* Paper No. 1 at 15; *see also* Paper No. 2.

Date: March 17, 2016

Respectfully Submitted,

Janine A. Carlan

Registration No. 42,387

ARENT FOX LLP

1717 K Street, NW

Washington, DC 20006

202.857.6000

Attorney for Petitioners Par Pharmaceutical,

Inc. and Amneal Pharmaceuticals LLC

CERTIFICATION OF SERVICE (37 C.F.R. §§ 42.6(e), 42.105(a))

The undersigned hereby certifies that the above-captioned "Petitioners Par Pharmaceutical, Inc.'s and Amneal Pharmaceuticals LLC's Response to Patent Owner's Notice Regarding New Arguments and Evidence in Petitioners' Reply," was served in its entirety on March 17, 2016, upon the following parties via e-mail:

John V. Biernacki

901 Lakeside Avenue

Cleveland, OH 44114

JONES DAY

North Point

jvbiernacki@jonesday.com

F. Dominic Cerrito

nickcerrito@quinnemanuel.com

Eric C. Stops

ericstops@quinnemanuel.com

Evangeline Shih

evangelineshih@quinnemanuel.com

Frank Calvosa

frankcalvosa@quinnemanuel.com

QUINN EMANUEL URQUHART &

SULLIVAN LLP

51 Madison Avenue

22nd Floor

New York, NY 10010

Counsel for Patent Owner Jazz Pharmaceuticals, Inc.

Patrick C. Gallagher Jordana Garallek

DUANE MORRIS LLP

DUANE MORRIS LLP

190 South LaSalle Street, Suite 3700 1540 Broadway

Chicago, IL 60603-3433 New York, NY 10036-4086

Counsel for Petitioner Wockhardt Bio AG



Respectfully Submitted,

Bradford C. Frese

Registration No. 69,772

Attorney for Petitioner Par Pharmaceutical, Inc.

Date: March 17, 2016 ARENT FOX LLP 1717 K Street, NW Washington, DC 20006 202.857.6000

